Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 4Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Leukemia 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinogenesis 1Brain Neoplasms 1

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × Monatide (IMS 3015) × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡